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Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery
platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to
some of the most exciting results in the field of gene therapy and, recently, to the market
approval of an AAV-based drug in Europe. With clinical development, however, it became
obvious that the host immune system represents an important obstacle to successful gene
transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxicT cell
responses directed against the AAV capsid encountered on human studies. While over the
past several years the field has acquired a tremendous amount of information on the inter-
actions of AAV vectors with the immune system, a lot of questions are still unanswered.
Novel concepts are emerging, such as the relationship between the total capsid dose and
the T cell-mediated clearance of transduced cells, the potential role of innate immunity in
vector immunogenicity highlighted in preclinical studies, and the cross talk between reg-
ulatory and effector T cells in the determination of the outcome of gene transfer. There is
still a lot to learn about immune responses in AAV gene transfer, for example, it is not well
understood what are the determinants of the kinetics of activation of T cells in response
to vector administration, why not all subjects develop detrimental T cell responses fol-
lowing gene transfer, and whether the intervention strategies currently in use to block T
cell-mediated clearance of transduced cells will be safe and effective for all gene therapy
indications. Results from novel preclinical models and clinical studies will help to address
these points and to reach the important goal of developing safe and effective gene therapy
protocols to treat human diseases.
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INTRODUCTION
Several clinical studies have shown long-term correction of the
disease phenotype following gene transfer (1–9). To attain this
goal, two main approaches have been used, one using an integrat-
ing viral vector (typically retroviral or lentiviral) to introduce the
therapeutic gene ex vivo into an autologous stem cell (10), the
other transferring the gene into a post-mitotic cell in vivo (11).
Viral vectors derived from adeno-associated virus (AAV) have
become the tool of choice for in vivo gene transfer, mainly because
of their superior efficiency in vivo (11), their tropism for a broad
variety of tissues, and their excellent safety profile. Therapeutic
efficacy following AAV vector gene transfer was documented in
several preclinical studies and, over the past decade, some of these
results were successfully translated to the clinic, leading to some
of the most exciting results in the field of gene therapy (11). The
recent market approval of the first AAV-based gene therapy prod-
uct in Europe (12, 13) constitutes additional evidence that the
field is progressing from proof-of-concept studies toward clinical
development.
However, human studies also highlighted some of the limita-
tions of in vivo gene transfer with AAV vectors, which were not
entirely identified in preclinical studies. In particular, it has been
shown that immune responses triggered by AAV vector-mediated
gene transfer may constitute an important obstacle to long-term
therapeutic efficacy and a safety concern.
Over the past 10 years, gene therapists have struggled with the
issue of immunogenicity of AAV vectors. The initial lack of ani-
mal models recapitulating the findings in human trials (14–16) has
made clinical observation crucial to understand the interactions
between AAV vectors and the immune system. While recent work
shows that it is possible to model human T cell responses to the
AAV capsid in mice (17), it is likely that human studies will remain
the main source of knowledge on immune responses in gene trans-
fer. In this review article, we will summarize the progress that has
been made in the understanding of T cell responses in AAV vector-
mediated gene transfer focusing on human studies, we will discuss
the current state of knowledge, and we will describe some of the
proposed strategies to modulate AAV vector immunogenicity.
WILD-TYPE AAV AND RECOMBINANT AAV VECTORS
Adeno-associated virus are small non-enveloped viruses with a
single-stranded DNA genome of ~4.7 kb composed by the rep and
the cap genes, which encode for the proteins involved in the life
cycle of the virus. The rep gene is involved in the virus replication,
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while the cap gene encodes for the three structural proteins, VP1,
VP2, and VP3, which form the viral capsid with a stoichiometry of
1:1:10, respectively (18), and for the assembly activating protein,
which targets newly synthesized capsid proteins to the nucleolus
and participates to their assembly into an icosahedral capsid (19).
The rep and cap genes are flanked by two inverted terminal repeats
(ITRs) that are needed as signals for packaging of the genome into
the viral capsid (20). AAV is not autonomously replicating as its
replication cycle depends on the coinfection with a helper virus
such as adenovirus or herpes simplex; this explains why AAV was
first isolated as a contaminant of an adenovirus preparation (21).
The exposure to AAV and helper virus may account for the gener-
ation of both antibody and memory T cell response to AAV. AAV
has never been associated with any known illnesses in humans
with the exception of reports of association between spontaneous
abortions and AAV infection (22). AAV vectors are derived from
wild-type AAV by replacing all the viral coding sequences in the
genome with an expression cassette for the transgene of interest.
The ITRs are the only viral sequences retained in AAV vectors.
AAV VECTOR:HOST INTERACTIONS
Like other viral gene transfer vectors, AAV vectors are com-
plex biological therapeutics, and the outcome of gene transfer is
dependent on the interactions between vector- and host-related
components (Figure 1). These interactions occur at multiple lev-
els, starting from the innate recognition of the vector capsid and
DNA genome (23), to the development of humoral (24) and cell-
mediated adaptive responses to the capsid and/or the transgene
product.
AAV VECTOR CAPSID
At the immunological levels, the AAV vector capsid is a replica
of the wild-type virion, therefore, the vector capsid antigen is
expected to be recognized by T cells like the wild-type AAV cap-
sid antigen. Despite this important similarity, however, vector
administration differs from natural infection as it involves the
introduction of large numbers of viral particles into an organism,
several logs more than in a natural infection (25), via routes sub-
stantially different from the natural route of exposure to AAV (i.e.,
mainly via the airways for wild-type AAV), and does not involve
active replication of the virus or presence of a helper virus, as AAV
vectors are delivered as preformed particles. These differences are
also characteristic of other viral gene transfer platforms, however,
unique features of AAV (e.g., their lower immunogenicity com-
pared to adenovirus) may account for the outcome of AAV gene
transfer in humans.
Because AAV vectors are non-replicating, it is generally
assumed that the AAV capsid remains immunologically detectable
within a transduced cell only for a defined period of time, which
may vary from few weeks to several months, depending on the
target tissue. Experiments in primates in the context of liver gene
transfer suggest that the capsid is still detectable by the immune
system several weeks following administration (26), indicated by
the fact that interruption of immunosuppression (IS) 8 weeks
after gene transfer results in a spike in anti-AAV antibodies. In
dogs, intact capsid was detectable by electron microscopy in the
retina up to 6 years following gene transfer (27), and a similar
FIGURE 1 | Adeno-associated virus vector:host interactions. The
components of AAV vectors interact with the host in determining the
outcome of gene transfer. For the AAV vector, the total capsid dose, the
genome (single-stranded vs. self-complementary, CpG content, etc.), and
the transgene product (to which the host may not be tolerant), represent
some of the elements that could contribute to vector immunogenicity. On
the host side, the characteristics of the target tissue (immunoprivilege,
presence of inflammation, tolerogenic properties, etc.), the genetic
background of the host (underlying disease-causing mutation, HLA
haplotype, etc.), and the pre-exposure to the wild-type virus, can contribute
to shape the overall response to vector delivery.
result was recently obtained in human muscle, in which immunos-
taining for capsid particles showed a positive signal 12 months
following vector administration (28). Finally, results in humans
undergoing AAV8 gene transfer for hemophilia B suggest that the
capsid antigen in transduced hepatocytes is still recognizable by
capsid-specific T cells 8–9 weeks following gene transfer (9).
Why the capsid persists for such a long period of time is not
clear at this point. There are several factors that may influence the
persistence of viral particles in a tissue, among them the vector
serotype and dose administered, the degree of vascularization of
the tissue target of transduction, the number of particles intro-
duced in a single injection site, and the possible immune response
to the vector itself, which may increase the rate of clearance of
the antigen. In vitro studies attempting to determine the half-life
of the capsid in transduced cells have been largely unsuccessful
in predicting the fate of the capsid, mainly because of the poor
infectivity of most serotypes in cell lines (29).
VECTOR DNA GENOME
Poorly defined until recently, the in vitro and in vivo interac-
tions of both the DNA genome and the capsid of AAV vectors
with the innate immune system were recently described by several
groups (30–35). Additionally, recently published results indicate
that the removal of CpG from the vector genome may contribute
to reduce the potential immunogenicity of the transgene product
(36). While these studies suggest that innate immunity to AAV
vectors may trigger adaptive immune responses to the capsid or
to the transgene product, there is no evidence that AAV vector
administration in humans result in acute inflammatory reactions,
although detailed studies in subjects undergoing AAV gene transfer
remain to be performed.
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TRANSGENE PRODUCT
Unlike the AAV vector capsid, which is not synthesized by infected
cells, the transgene product is expressed for a long time after target
tissue transduction (37–39). Vector-encoded transgene product
may be recognized as a foreign antigen, especially if the recipient
of gene transfer is not tolerant to the protein encoded by the vector,
thus triggering immune responses that can result in production of
transgene-specific neutralizing antibodies (40) or triggering of T
cell responses directed against transgene-expressing transduced
cells (41).
Preclinical studies suggest that the tissue target of transduction
plays a fundamental role as determinant of transgene immune
responses in gene transfer. For example, preclinical studies of
intramuscular delivery of AAV vectors suggest that this approach
carries a higher risk of triggering immune responses to the trans-
gene (42) compared to other tissues such as the liver (43), and that
the underlying disease-causing mutation is a major determinant
of the risk of developing an immune response to the therapeutic
transgene product following AAV-mediated gene transfer to the
muscle (44). Conversely, delivery of AAV vectors to the muscle via
the vasculature seem to reduce considerably the immunogenic-
ity of the therapeutic transgene (45–47), suggesting that the more
widespread and uniform transduction of muscle achieved with
this route of vector delivery lowers transgene immunogenicity.
Clinical results accumulated thus far on intramuscular delivery
of AAV vectors seem to indicate that the approach is safe, as no
subject enrolled in trials of intramuscular gene transfer devel-
oped anti-transgene immunity (13, 48, 49). Transgene-specific
cell-mediated immunity was documented in only one study in
which pre-existing immunity to dystrophin seemed to trigger the
expansion of dystrophin-specific CD8+ T cell clones (41).
Differently form muscle, a number of studies showed that
expression of a transgene in the liver is associated with induction of
antigen-specific tolerance (43, 50–59). This was demonstrated for
several antigens and in various animal models, including animals
that were first immunized and then tolerized against the same anti-
gen used for immunization using liver gene transfer (52, 55, 56).
Results from clinical gene transfer studies seem to support the
hypothesis that AAV vector-mediated liver gene transfer is associ-
ated with tolerance, as no subject dosed with AAV vectors in the
liver developed an immune response directed against the trans-
gene product, including individuals carrying null mutations in
the disease-causing gene (9, 60).
Lastly, one important point to keep in mind when discussing
transgene immunity is that most of the clinical experience to date
derives from studies in which cross-reactive immunologic mater-
ial (CRIM) positive subjects and subjects with prior exposure to
the therapeutic protein [e.g., recombinant or plasma-derived fac-
tor IX (FIX) for hemophilia B patients] were enrolled (9, 48, 60,
61). These categories of subjects are at lower risk of developing
immune responses to the donated therapeutic gene, thus a careful
assessment of the immunogenicity of the transgene in gene trans-
fer will be necessary before enrolling previously untreated patients
in gene transfer trials. Finally, also the disease state of the organ
targeted with gene transfer can influence the magnitude of the
immune responses observed following AAV vector-mediated gene
transfer (62–64).
CAPSID ANTIGEN INTRACELLULAR PROCESSING AND MHC
CLASS I PRESENTATION
Cell transduction with AAV vectors begins with binding of the
virion to the cell surface proteins and carbohydrates, an event that
is followed by endocytosis. The receptor and co-receptors used
for cell entry vary among serotypes, although the receptors for
all serotypes have not been identified yet. The steps of endosomal
escape, nuclear transport, and vector uncoating are not completely
understood in terms of timing or mechanism, this in part due to
their complexity and the large number of pathways and compart-
ments potentially involved in the process of cell transduction. The
intracellular fate of AAV2 has been the most extensively inves-
tigated, because several cell lines are readily transduced by this
serotype and because monoclonal antibodies recognizing AAV2
intact particles and capsid proteins were the first available. Of
interest to this review article is the ability of the capsid antigen
to be processed and cross-presented on MHC class I (MHC I)
by transduced cells (e.g., hepatocytes). Since the initial findings
on the immunogenicity of AAV2 vectors in human trials (60),
the ability of replication-deficient AAV vectors to gain access to
MHC I via cross-presentation has been object of debate, and sev-
eral alternative hypothesis were formulated to explain why AAV2
vectors were immunogenic in humans but not in animal mod-
els. These included the possibility of preferential uptake of certain
AAV serotypes by dendritic cells, the expression of Cap sequences
packaged into AAV vectors, and the expression of alternative open
reading frames within the transgene cDNA, which would gener-
ate aberrant proteins recognized as offending antigens by the host
immune system [reviewed in Ref. (65)]. Several years of studies
in preclinical models and, most importantly, in human trials (9)
helped developing a better understanding of immune responses
to AAV vectors, supporting the idea that capsid-specific T cell
responses were responsible for clearance of transduced cells.
At the intracellular level, it has been shown that the cap-
sid is substrate for ubiquitination (66, 67), and that proteasome
inhibitors, or mutation of surface exposed tyrosine residues that
normally undergo phosphorylation and ubiquitination, enhance
transduction by enhancing nuclear uptake of virus (68, 69). Data
supporting the hypothesis that the AAV capsid antigen is processed
by the proteasome and presented on MHC I come from CTL assays
performed using AAV-transduced human hepatocytes as targets,
and HLA-matched capsid-specific CD8+ T cells as effectors (70).
The fact that target cell lysis can be inhibited specifically using a
capsid antigen-specific soluble T cell receptor (TCR) to block T cell
access to the target cell (70) further confirms that the AAV capsid
antigen is processed by transduced cells and presented on MHC I.
Presentation of antigen in the context of MHC I was also demon-
strated using a T cell line engineered to express luciferase when
recognizing the capsid antigen (71). In this study, levels of antigen
presentation were directly correlated with the multiplicity of infec-
tion used in the assay, and the proteasome inhibitor bortezomib
blocked antigen presentation. These results are in agreement with
results from clinical studies, which suggest the existence of a cor-
relation between vector dose and magnitude of T cell responses to
the capsid.
Recent work from Li et al. (72) indicates that the endosomal
escape of vector is not only the pivotal step in cell transduction
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but is also fundamental for capsid antigen presentation. While this
is not completely surprising, the study also indicates that empty
capsids, AAV particles that fail to incapsidate a DNA genome,
are less likely to be presented onto MHC I. This result is some-
what in contrast with previous data showing that empty capsids
do flag transduced cells for T cell recognition (70). One possible
explanation for this difference is that the two studies used dif-
ferent strategies to detect antigen presentation: ovalbumin TCR
transgenic T cells and a capsid carrying the ovalbumin SIINFEKL
epitope in one study (72), or human peripheral blood mononu-
clear cells (PBMCs) expanded against a the native AAV epitope
VPQYGYLTL to track presentation of native AAV2 capsid anti-
gen (70). Immunogenicity of empty vs. full AAV capsids is an
important pending question for the field, particularly given the
fact that empty capsids may play an important beneficial role in
allowing for vector transduction in the presence of neutralizing
antibodies (73).
Although there is no direct evidence that intracellular process-
ing and presentation of AAV onto MHC I differ among serotypes,
anecdotal evidence supporting this hypothesis comes, for exam-
ple, from the observation that the administration of AAV2 and
AAV8 vectors to the liver of humans at similar doses results in
different kinetics of activation cytotoxic T cell immunity against
the transduced hepatocytes (9, 60, 74). Whether these differences
can be ascribed to the vector serotype only is unknown, as in vitro
studies comparing AAV serotypes have been challenging due to
differences in efficiency of AAV transduction among serotypes.
Conversely, in vivo preclinical studies show somewhat contrasting
results, some suggesting for example that AAV2 and AAV8 have
identical kinetics of T cell induction (75), and others showing that
AAV2 and AAV8 do differ in their ability of triggering T cell pro-
liferation (76). Serotype-specific differences are also supported by
data generated with an adoptive T cell transfer model in mice, indi-
cating that AAV8 remains immunologically detectable longer than
AAV2 following systemic gene transfer to target the liver (17, 76).
In conclusion, several studies identified the key intracellular
AAV trafficking steps that are involved in cell transduction and
capsid antigen presentation. Whether there is one leading path-
way for antigen cross-presentation or rather multiple alternative
pathways concur to MHC I presentation (77) of capsid remains to
be defined. Most importantly, the significance of in vitro findings
has to be proven in vivo, as kinetics and pathways might differ
substantially in living organisms compared to cell lines.
T CELL RESPONSES TO AAV IN HUMAN STUDIES
Several studies on the seroprevalence of AAV in humans suggest
that exposure to the wild-type virus mostly occurs early in life (78–
80). Similarly, monitoring of T cell reactivity to the AAV2 capsid
conducted in humans undergoing splenectomy for non-malignant
indications shows that about two-thirds of adults >25 year-old
carry a pool of T cells that can produce IFN-γ in response to
AAV2 capsid peptides, while only a small proportion of subjects
<5 years old present T cell reactivity to the capsid (81). Veron et al.
(82) conducted a similar survey for AAV1 in PBMCs from healthy
donors. In this study, an overall frequency of respondents of about
30% was documented. The difference in frequency of subjects car-
rying capsid-specific T cells in the two studies may be due to the
fact that reactive T cells fail to circulate in peripheral blood at high
frequency [as previously suggested in Ref. (74)], or to the different
restimulation protocols used (a peptide library was used in the
AAV2 study vs. lentiviral vectors expressing capsid were used in
the AAV1 study), or else it may reflect inherent differences in the
frequency of subjects exposed to AAV2 vs. AAV1.
Two aspects of capsid T cell reactivity are worth noting, the first
is that the high degree of conservation of the AAV capsid amino
acid sequence (83) results in a high degree of cross-reactivity of
T cell responses across serotypes (74). The second aspect is that
B and T cell responses to AAV seem to be uncoupled, as subjects
positive for anti-AAV antibodies may not present detectable T cell
reactivity to the capsid and, vice versa, subjects with detectable T
cell reactivity to AAV in PBMC have lower anti-capsid antibody
titers (82). This suggests that, following exposure to AAV, certain
individuals may develop a Th1 response to the antigen, while oth-
ers develop a predominantly Th2 response. Future studies will be
required to clarify the relationship between B and T cell responses
to AAV in the context of the natural infection with the virus.
LIVER-DIRECTED GENE TRANSFER
The importance of T cell immunity to the AAV capsid in terms
of both safety and efficacy of AAV gene transfer in humans was
initially evidenced in the first clinical trial in which an AAV2 vector
was introduced into the liver of severe hemophilia B subjects (60).
In this study, upon AAV gene transfer to liver, two subjects devel-
oped transient elevation of liver enzymes and loss of FIX transgene
expression around week 4 post vector delivery due to the immune
rejection of transduced hepatocytes mediated by capsid-specific
CD8+ T cells (74).
While conceptually these findings are not surprising, as antivi-
ral immunity is expected to recognize virus infected cells and clear
them, this was the first instance in which a cytotoxic immune
response directed against the AAV capsid was observed in the con-
text of gene transfer. Preclinical animal studies failed to predict
or to recapitulate the findings in humans, and initial attempts to
model the induction of destructive T cell responses in mice have
been mostly unsuccessful until recently (17).
The recent findings in a clinical trial of AAV8 gene transfer of
FIX to the liver of subjects affected by severe hemophilia B (9)
confirmed results in the previous AAV2 trial and supported the
hypothesis that AAV capsid antigen is processed and presented
onto MHC I by vector-transduced hepatocytes where it is rec-
ognized by capsid-specific CD8+ T cells, leading to clearance of
vector-transduced hepatocytes, transaminase elevation, and loss
of FIX transgene expression.
In particular, in the AAV8-FIX study vector administration
resulted in the activation of capsid-specific CD8+ T cells, with an
increase in liver enzymes that required intervention with corticos-
teroids detected in four out of six subjects (9, 84) from the high-
dose cohort, who received 2× 1012 vg/kg of vector, ~8–9 weeks
after vector delivery. Results from this clinical study suggest that a
short course of steroids, administered at the time of liver enzymes
elevation and loss of transgene expression, can at least partially res-
cue transgene expression. This study also highlights differences in
kinetics of T cell responses between the AAV2 and the AAV8 liver
trials, as liver enzyme elevation in the AAV2 trial was observed
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around week 4 following vector delivery (60), as opposed to the 8-
to 9-weeks in the AAV8 trial (9). It is not clear at this point what
is the likely explanation for this difference.
One important emerging aspect of AAV capsid-driven capsid
T cell reactivity in humans is that capsid-specific T cell responses
seem to be detected in a dose-dependent fashion, a result consis-
tent with published in vitro antigen presentation data (70). Above
a certain threshold of capsid antigen dose, the activation of capsid-
specific T cells results in loss of transduced hepatocytes. Whether
at vector doses higher than those tested thus far all subjects will
mount a T cell response that will result in loss of transgene expres-
sion, and whether steroids will effectively control capsid T cells at
all vector doses, is not clear at this point. Several factors are like
to influence the outcome of vector administration in humans in
terms of T cell reactivity, thus complicating the interpretation of
results, among them the HLA type of the subjects infused, the con-
comitant presence of inflammation in the target tissue, and other
vector-specific features that may enhance immune responses to
the vector, the transgene, or both.
GENE TRANSFER TO THE MUSCLE
Adeno-associated virus vector-induced T cell immunity is not
unique to liver-directed gene transfer. Monitoring of capsid T cell
responses has been performed in the context of several muscle-
directed gene transfer clinical studies (41, 85–92) as well. In agree-
ment with the findings in AAV liver gene transfer studies, results
accumulated for muscle gene transfer suggest that the magnitude
of T cell responses directed against the AAV capsid correlates with
the dose of vector administered (65, 92). Following intramuscular
AAV vector delivery, an increase in frequency of circulating reac-
tive T cells in PBMC is observed at higher vector doses (91). In
some cases, detection of capsid T cell activation in PBMC corre-
lated with lack of transgene expression in vector injected muscle
(89, 91); while in other studies the detection of capsid T cells in
PBMC seemed to have no effect on transgene persistence (28).
Immunosuppression has been used in some of the muscle gene
transfer studies conducted thus far to modulate capsid immuno-
genicity (13). Whether this helped the persistence of transgene
expression is not completely clear due to the lack of readily
detectable efficacy endpoints and the fact that IS itself compli-
cates immunomonitoring as it is likely to modify capsid-directed
T cell responses.
In a recent study of intramuscular gene transfer for α1-
antitrypsin deficiency (92), vector administration was associated
with detection of capsid-specific T cell reactivity and increase in
serum creatine kinase in some subjects around day 30 post vector
administration. Furthermore, activation of both CD4+ and CD8+
T cells in peripheral blood and T cell infiltrates in muscle biopsies
were detected. T cell reactivity against the AAV capsid antigen did
not seem to result in clearance of transduced muscle fibers or loss
of transgene expression, a finding that may be explained by the
fact that significant amounts of CD4+CD25+FoxP3+ regulatory
T cells (Tregs) were found in muscle biopsies (28). Whether the
local induction of Tregs is a phenomenon unique to muscle or to
the α1-antitrypsin transgene (93) remains to be established. How-
ever, these findings indicate that proinflammatory and tolerogenic
signals may be concomitantly elicited by vector administration and
may concur in determining the outcome of gene transfer. Similarly,
apoptosis of transgene reactive T cells in muscle has been docu-
mented in mice (94) and in humans (90), indicating that additional
factors are involved in the modulation immunogenicity of vector
and transgene other than the target organ alone.
The inability of collecting tissue biopsies in the AAV trials for
hemophilia conducted thus far prevented investigators from com-
paring results between liver and muscle gene transfer, thus leav-
ing open important questions on the relevance of tissue-specific
features that may influence vector immunogenicity.
GENE TRANSFER TO IMMUNOPRIVILEGED BODY SITES
Adeno-associated virus vectors have been administered to humans
in several eye- (95) and brain- (96–102) targeted gene transfer
trials. So far, doses tested in these immunoprivileged body com-
partments were lower compared to the doses tested in the liver
or muscle trials, and they fail to elicit significant antibody or cell-
mediated immune responses to capsid or transgene product. While
these results strongly support the safety of gene transfer to eye and
brain, future studies will help to understand whether the immune
privilege is maintained at all vector doses, especially given the fact
that some AAV vector serotypes can escape the blood–brain barrier
(103), thus resulting in systemic exposure to the vector.
OVERCOMING T CELL IMMUNITY TO AAV
More than 10 years have passed since the initial AAV2 FIX trial.
The field of in vivo gene transfer with AAV vectors has progressed
enormously thank to a multitude of preclinical and clinical stud-
ies that clarified the nature of anti-capsid immune responses and
tested the efficacy of strategies aimed at preventing or modulating
these responses. In this section of our review article, we will dis-
cuss some of these strategies, with particular emphasis on those
already tested in the clinic.
REDUCE THE TOTAL CAPSID ANTIGEN DOSE
Results from the AAV8 hemophilia trial (9, 84) suggest that lower
vector doses may not trigger destructive T cell responses to the
capsid. In this study, subjects who received vectors doses up to
6× 1011 vg/kg did not experience increase in liver enzymes or loss
of transgene expression, at the same time levels of FIX transgene
were just above the threshold for therapeutic efficacy. Different
strategies are being tested to maintain the total capsid dose low
while increasing therapeutic efficacy. One is to use hyperactive
variants of the therapeutic protein (104–106), or stronger pro-
moter elements (107), or else codon-optimized transgenes (108,
109). All these maneuvers are either being tested in the clinic or
about to enter clinical trials and results will be available soon.
Engineering the AAV capsid to prevent its presentation onto
MHC I (17, 69) or administration of proteasome inhibitors (71)
to block processing of capsid antigen are also strategies that have
been proposed to reduce capsid antigen load following vector
administration. These strategies are also associated with higher
transduction efficiency in animal models (71, 110), thus they could
potentially allowing to decrease the therapeutic dose; however, the
role of alternative antigen presentation pathways should be taken
into account when evaluating this strategy. Furthermore, the use of
proteasome inhibitors like bortezomib is not devoid of potentially
serious side effects (111).
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The use of AAV vector preparations devoid of empty capsids
is also being tested as a strategy to reduce the overall antigen load
associated with gene transfer. While clearly this results in lower
total amounts of capsid being administered, in the negative side it
may render vectors more susceptible for antibody-mediated neu-
tralization (73). The jury is still out on the role of empty capsids
in gene transfer, with some reports suggesting that these particles
are not immunogenic (72), others arguing that they are detrimen-
tal for transduction efficiency (112), and recent reports showing
that they are beneficial in the presence of anti-AAV neutralizing
antibodies (73).
USE TRANSIENT IMMUNOSUPPRESSION
One potential advantage of the use of IS the context of AAV gene
transfer is that, differently from organ transplant or autoimmune
disease, the duration of the intervention is expected to be rela-
tively short (9). Initial studies of gene transfer with IS favored
the idea of treating subjects upfront, starting just before or at
the time of vector administration (26, 58, 113–116). The advan-
tage of this approach is that any immune response occurring
after vector deliver would be prevented, the main disadvantage
consist in the fact that IS would prevent efficient immunomon-
itoring, thus would not allow to study the nature and kinetics
of immunity to AAV. Additionally, treating all subjects with IS
may not be necessary, as some may not develop immunity to the
vector (9, 84).
Aside from the obvious higher risk of infection, IS may also
influence induction of Tregs (58), which are fundamental for the
maintenance of transgene tolerance in liver (43) gene transfer and
seem to play an important role in muscle gene transfer (28). Recent
reports show impaired transduction levels under IS with mycophe-
nolate mofetil (113), others report a longer plasma half-life of
vector in non-human primates receiving IS (114). These are all
evidences that interactions of IS with viral gene transfer are quite
complex and may result in unexpected findings.
The use of transient IS with steroids at the time of liver enzyme
elevation is a relatively novel concept in the field of gene transfer
that has been successfully adopted in the AAV8 hemophilia trial. In
this study, a mild elevation of liver enzymes has been immediately
treated with high-dose prednisolone, resulting in the prevention
of what appeared to be an immune-mediated clearance of AAV8
transduced hepatocytes. The main advantage of the approach is
that not all subjects were exposed to IS, in fact only those who had
increased liver enzymes received prednisolone. The challenge of
the approach is that endpoints of liver (or other organ) immuno-
toxicity may not be always obvious, making a targeted intervention
hard. In these latter cases, upfront IS may be necessary; however,
the key question revolves around the timing and the duration of
this approach. Additionally, steroids may not work in some sub-
jects or at high vector doses. These concerns will be addressed in
future studies.
In conclusion, one important consideration about IS regimens
and timing of intervention is about the immune state of infused
subjects. Some individuals may in fact be recently primed by
natural infections with wild-type AAV, or else could have been
previously enrolled in gene therapy protocols (in case of vector
readministration). Immune responses to the vector capsid in these
subjects may be expected to be faster and stronger, thus warranting
particular attention.
CANWE TOLERIZE SUBJECTS AGAINST THE AAV CAPSID?
As an alternative to IS, the induction of Tregs specific to the AAV
capsid can result in sustained expression of the transgene with no
induction of destructive T cells.
MHC class II epitopes found in human IgG (117) have been
described to induce proliferation of Tregs and suppress Th1 and
Th2 immune responses (117–120). These peptides, named Tre-
gitopes, have been used to modulate CD8+ T cell responses to
AAV, resulting in suppression of cytotoxic responses against AAV-
transduced cells and expansion of Tregs in vitro. Additional studies
in vivo (118), in which Tregitopes were co-expressed with the cap-
sid antigen, resulted in modulation of CD8+ T cell responses to
the capsid antigen itself following adenoviral vector-mediated vac-
cination. While results in vitro suggest that the approach leads
to antigen-specific tolerance (118), additional studies are needed
to test if antigen-specificity is conserved in vivo, whether the
approach is safe, and ultimately, how to translate this strategy to
the clinic.
CONCLUSION
Since the initial proof-of-concept studies, the field of in vivo gene
transfer has progressed enormously. Experience from the clini-
cal translation of AAV vector-based gene transfer strategies has
highlighted the challenges and helped optimize the choice of the
AAV vector serotype, the delivery methods, and has highlighted
some of the limitations of the approaches tested. In particular,
the interactions between the human immune system and all the
components of gene therapy vectors seem to represent one of the
major limitations to long-lasting therapeutic efficacy.
The small scale of gene transfer trials for rare diseases, the het-
erogeneity of vector serotypes, transgenes, and doses tested, and
the ability of measuring the endpoints of therapeutic efficacy have
been an obstacle to the advancement of knowledge. Furthermore,
individual variability associated for example with HLA haplotype
and with the underlying disease state also represents an added layer
of complexity to data interpretation.
Gene therapists should not forget that immune responses trig-
gered by gene transfer must be understood and studied as a
complex network of interactions; as such, the outcome of gene
transfer in immunological terms is influenced by both innate
and adaptive immunity, which are influenced by the nature
of the vector, transgene, route, etc. Future immunosurveillance
studies conducted in clinical gene transfer studies will provide
the basis for a better understanding of the determinants of T
cell responses in AAV-mediated gene transfer, for example, the
role of target tissue inflammation due to the underlying dis-
ease. Standardization of technologies used for monitoring of T
cell responses (121, 122) will help to correlate them with clini-
cal outcomes and, eventually, devise novel strategies around the
issue.
Despite these challenges, the field has acquired critical informa-
tion from the studies conducted thus far, which allowed to address
the issue of vector immunogenicity. The results of these efforts
are evident, long-term follow up data from AAV gene transfer
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trials show many examples of long-lasting therapeutic efficacy.
And results accumulating suggest that once transgene expres-
sion is established, and immune responses avoided, multi-year
therapeutic efficacy is a goal attainable in humans.
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